U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07610837) titled 'Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis' on April 30.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.
Study Start Date: May 07
Study Type: INTERVENTIONAL
Condition:
Liver Fibrosis
Hepatic Cirrhosis
Intervention:
DRUG: AZD2389
potent, selective, first-in-class, small molecule oral inhibitor of FAP and is being developed for the treatment of CLDs with advanced hepatic fibrosis including cirrhosis.
...